Drug Approval | December 21, 2021
U.S. FDA approves ANI’s rifabutin capsules, launch soon
The capsules are the generic version of the reference listed drug Mycobutin
The capsules are the generic version of the reference listed drug Mycobutin
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research
The primary objective of the ongoing trial is to determine whether ambrisentan can prevent the progression to respiratory failure and reduce the need for mechanical ventilation, among others
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
Vakrangee through its Nextgen Kendras and BharatEasy Mobile Superaap will now be able to provide medicines & healthcare services in remote areas of the country
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
Subscribe To Our Newsletter & Stay Updated
